Nearly 9% Abandoned in Five Sessions: Exosens Share (Optronic) Falls Back
The Bordeaux-based optronics company is declining this Thursday, in a Paris market oriented downwards. The movement erases Wednesday's rebound and places the security back in a configuration of decline that the past week had already outlined.
A Decline That Extends the Slide Below Moving Averages
Exosens loses 2.59% to €54.55, against €56 at the previous close, while the SBF 120 declines 0.94% and the CAC 40 0.87%. The security is thus classified in the lower part of the index, without ranking among its heaviest declines. Over the week, the decline reaches 8.78%, a movement that leaves the security below its MA20 (€58.76, gap of 7.16%) as well as below its MA50 (€59.81) and its MA200 (€59.90). The price thus remains more than 8% below both long-term averages, after a Wednesday rebound that did not hold.
The support at €54.15 is now less than 1% from the price, while the RSI at 41 remains in neutral territory. This session follows several back-and-forths since mid-September. The group had raised its 2026 targets on September 17, which had propelled the security to the top of the SBF 120, before gains eroded session after session.
Targets Raised in September and a Publication Expected Late October
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On September 17, the group revised upward its ambitions for 2026, with approximately 20% growth in its revenue and approximately 25% growth in its adjusted EBITDA, with revenue potentially reaching €570 million. The next day, two brokerages had raised their targets, and Bernstein set its target at €74 on September 23. The analyst consensus thus remains significantly above the current price, but the market did not follow this increase over time.
Over three months, the security loses 8.17%, while it maintains a gain of 23% over one year. The next appointment is the publication of nine-month results, expected on October 27.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.